18 May 2013
Keywords: novartis, rasilez, may, cut, heart, attack, severity
Article | 10 September 2007
Drug major Novartis says that its high blood pressure treatment Rasilez (aliskiren), which was co-developed with fellow Swiss firm Speedel ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 September 2007
17 May 2013
© 2013 thepharmaletter.com